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Abstract 
Background: Lung remodeling and pulmonary fibrosis are serious, life‑threatening conditions resulting from dis‑
eases such as chronic severe asthma and idiopathic pulmonary fibrosis (IPF). Preclinical evidence suggests that JNK 
enzyme function is required for key steps in the pulmonary fibrotic process. However, a selective JNK inhibitor has not 
been investigated in translational models of lung fibrosis with clinically relevant biomarkers, or in IPF patients.
Methods: The JNK inhibitor CC‑930 was evaluated in the house dust mite‑induced fibrotic airway mouse model, in 
a phase I healthy volunteer pharmacodynamic study, and subsequently in a phase II multicenter study of mild/mod‑
erate IPF (n = 28), with a 4‑week, placebo‑controlled, double‑blind, sequential ascending‑dose period (50 mg QD, 
100 mg QD, 100 mg BID) and a 52‑week open‑label treatment‑extension period.
Results: In the preclinical model, CC‑930 attenuated collagen 1A1 gene expression, peribronchiolar collagen deposi‑
tion, airway mucin MUC5B expression in club cells, and MMP‑7 expression in lung, bronchoalveolar lavage fluid, and 
serum. In the phase I study, CC‑930 reduced c‑Jun phosphorylation induced by UV radiation in skin. In the phase 
II IPF study, there was a CC‑930 dose‑dependent trend in reduction of MMP‑7 and SP‑D plasma protein levels. The 
most commonly reported adverse events were increased ALT, increased AST, and upper respiratory tract infection (six 
subjects each, 21.4 %). A total of 13 subjects (46.4 %) experienced adverse events that led to discontinuation of study 
drug. Nine out of 28 subjects experienced progressive disease in this study. The mean FVC (% predicted) declined 
after 26–32 weeks at doses of 100 mg QD and 100 mg BID. Changes in MMP‑7, SP‑D, and tenascin‑C significantly cor‑
related with change in FVC (% predicted).
Conclusions: These results illustrate JNK enzymatic activity involvement during pulmonary fibrosis, and support sys‑
temic biomarker use for tracking disease progression and the potential clinical benefit of this novel intervention in IPF.
Trial registration ClinicalTrials.gov NCT01203943
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, pro-
gressive, fibrosing interstitial lung disease of unknown 
etiology. Primarily occurring in older individuals, IPF is 
characterized by progressive worsening in dyspnea and 
pulmonary function [1]. The exact mechanism underly-
ing IPF remains to be elucidated. According to current 
hypotheses, repetitive epithelial injury, aberrant wound 
healing, endoplasmic reticulum stress, and abnormal 
epithelial-mesenchymal interactions are crucial events 
in the fibrotic process [2–4]. Patients with IPF have a 
poor prognosis, with median survival of 2–4 years after 
diagnosis [5–8]. Recently, two drugs, pirfenidone and 
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nintedanib, have shown efficacy in slowing disease pro-
gression in IPF, marking a significant advance in phar-
macological treatment [9, 10]. However, there remains a 
strong unmet need for additional therapeutics that will 
further improve patient outcomes.
Multiple biomarkers have been proposed to be associ-
ated with IPF because they are expressed differentially 
in IPF patients compared with healthy individuals, are 
associated with survival of IPF patients, or play a known 
or hypothesized role in wound healing and/or the pul-
monary fibrotic process [11]. Matrix metalloproteinases 
(MMP) degrade extracellular matrix components, and 
endogenous inhibitors of MMPs block their protease 
activity [11]. Increased MMP-1 and MMP-7 protein con-
centrations were observed in the plasma, bronchoalveo-
lar lavage fluid (BALF), and lung tissue of IPF patients, 
with MMP-7 concentrations negatively correlated with 
forced vital capacity (FVC) and diffusing capacity for 
carbon monoxide (DLCO) [11]. The plasma MMP-7 level 
has been included, along with gender, FVC, and DLCO, 
in a predictive index of mortality in IPF patients [8]. Sur-
factant protein A (SP-A) and surfactant protein D (SP-D) 
are C-type lectins in the collectin subgroup, expressed 
by alveolar epithelial cells [12]. SP-A and SP-D levels in 
serum are elevated in patients with IPF compared with 
healthy subjects and/or those with other interstitial lung 
diseases. Moreover, increased levels of serum SP-A and 
SP-D have been associated with increased mortality in 
IPF [13, 14]. Tenascin-C, an extracellular matrix protein 
expressed during wound healing, has been identified at 
elevated levels in the fibroblast foci and in the basement 
membrane regions under the epithelium of honeycomb 
lesions in the lungs of IPF patients [15]. Myofibroblasts 
were found to express the highest tenascin-C levels 
[16]. Other proposed IPF biomarkers include Krebs von 
den Lungen-6 antigen (KL-6) [17], CCL-18 [18], mono-
cyte chemotactic protein-1 (MCP-1; also known as CC 
chemokine ligand 2) [19], tissue inhibitor of metallo-
proteinase-1 (TIMP-1) [20], and plasminogen activator 
inhibitor-1 (PAI-1) [21].
The c-Jun N-terminal Kinase (JNK) pathway is acti-
vated by multiple cytokines and exposure to environmen-
tal stress [22]. JNK activation induces phosphorylation 
of c-Jun and other downstream molecules, which in turn 
regulate expression of genes involved in cell growth, dif-
ferentiation, survival, and apoptosis. Several processes 
leading to fibrosis may be associated with JNK pathway 
activation. Multiple cell types in the lungs of IPF patients, 
including alveolar epithelial cells, vascular endothelial 
cells, alveolar macrophages, smooth muscle cells, and 
lymphocytes, overexpress phosphorylated JNK, with lev-
els reflecting the degree of fibrosis [23]. The pro-fibrotic 
cytokine, Transforming Growth Factor β1 (TGF-β1), 
stimulates transformation of human lung fibroblasts 
into myofibroblasts that produce collagen and other 
extracellular matrix components, a transformation pro-
cess blocked by JNK inhibition [24]. Pulmonary fibro-
blasts also proliferate in response to TGF-β1 through the 
release of fibroblast growth factor-2, which induces phos-
phorylation of JNK and p38 mitogen-activated protein 
kinases [25]. JNK1-deficient mice are protected against 
TGF-β1- and bleomycin-induced pro-fibrotic gene 
expression and pulmonary fibrosis [26].
CC-930 is a potent, selective, and orally active JNK 
inhibitor that competes with adenosine triphosphate 
in the JNK-dependent phosphorylation of c-Jun [27]. 
CC-930 inhibits all JNK isoforms with Ki (inhibitory 
constant) values of 5–61  nM. This compound exhib-
its acute anti-inflammatory effects in vivo. For example, 
CC-930 reduced tumor necrosis factor alpha (TNF-α) 
by 23 and 77 % at oral doses of 10 and 30 mg/kg, respec-
tively, in the rat LPS-injection model [27]. To evaluate the 
anti-fibrotic potential of CC-930, the mouse bleomycin-
induced model of lung inflammation and fibrosis was 
initially chosen to demonstrate chronic efficacy. CC-930 
was tested prophylactically at 25, 50, 100 and 150 mg/kg 
prior to instillation of bleomycin, followed by 13 days of 
twice-daily dosing. A statistically significant inhibition 
of white blood cells, monocytes, and lymphocytes was 
observed in the bronchoalveolar lavage at all doses com-
pared with the vehicle control, and lung fibrosis scores 
were reduced by 18–32  % in a dose-dependent manner 
[27]. CC-930 also blocked myofibroblast differentiation, 
collagen accumulation, and fibrosis development in a 
dermal fibrosis model [28]. In vitro, CC-930 suppressed 
pro-fibrotic gene expression by dermal fibroblasts iso-
lated from patients with systemic sclerosis: collagen 1A1, 
collagen 1A2, and fibronectin mRNA levels were reduced 
to 71, 61 and 55 % of control by 1 μM CC-930. In the ble-
omycin-induced dermal fibrosis mouse model, CC-930 
treatment dose-dependently reduced dermal thickening 
by up to 45 %, prevented the accumulation of collagen as 
measured by hydroxyproline content by up to 53 %, and 
completely inhibited the differentiation of fibroblasts 
into active myofibroblasts at doses of 150  mg/kg. At 
these doses in the TSK1 tight-skin mouse model, CC-930 
reduced hypodermal thickening in a dose-dependent 
manner by up to 85 %, and completely prevented myofi-
broblast differentiation [28]. We recently reported that 
JNK1-deficient mice showed decreased pulmonary fibro-
sis without reduced inflammation in house dust mite 
(HDM)-induced lung remodeling in the mouse [29].
These cumulative data on CC-930 pharmacology, 
coupled with an appreciation for the dependency of 
fibrosis on the JNK pathway, as well as the remaining 
unmet medical needs in IPF medical treatment, led us 
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to evaluate CC-930 in a series of nonclinical and clinical 
studies aimed at developing a novel therapy for IPF. Here, 
we show that CC-930 inhibits HDM-induced pulmonary 
fibrosis with minimal effects on inflammation. We fur-
ther present results from two clinical studies of CC-930. 
The first clinical study was designed to provide proof of 
activity that CC-930 inhibits JNK in healthy volunteers 
and to select doses for evaluation in IPF patients. The 
second study was designed to evaluate the safety, phar-
macokinetics, and pharmacodynamics of CC-930 in IPF 
patients. Information on disease progression was evalu-
ated as a secondary objective. The pharmacodynamic 
effects of CC-930 on select blood biomarkers associated 
with IPF were used to assess the relationships among the 
CC-930 dose, exposure, efficacy, and biologic activity.
Methods
The methodology used in the HDM-induced lung remod-
eling model is described in the Additional file 1.
Study approval
All animal studies were approved by the Institutional 
Animal Care and Use Committee (IACUC) at the Uni-
versity of Vermont. Both clinical studies were conducted 
in accordance with the ethical principles outlined in the 
Declaration of Helsinki and in compliance with Good 
Clinical Practice and all local regulatory requirements. 
The study protocols were approved by the IRB or inde-
pendent ethics committee at each site, and all patients 
provided written informed consent before enrollment.
Experimental design
The phase I clinical study of CC-930 in healthy volunteers 
was a single-center, randomized, double-blind, placebo-
controlled, multiple-dose, 3-way crossover study that was 
designed to evaluate the effect of CC-930 on JNK activ-
ity after UVB irradiation of human skin. The study was 
run by MDS Pharma Services (Tempe, AZ) from August 
to October 2009. Fifteen healthy subjects were rand-
omized to 1 of 3 dosing sequences, with five subjects per 
sequence: oral placebo, CC-930 75  mg QD, or CC-930 
200 mg QD for 6 days. There was a minimum of a 7-day 
washout between dosing periods. Compliance with med-
ication dosing was monitored by maintaining an accu-
rate record of all study drug administrations (including 
dispensing and dosing) on the test compound pages of a 
subject’s case report form.
The phase II clinical study of CC-930 in IPF patients 
was a multicenter study, open to enrollment from Janu-
ary 2011 to August 2012, which consisted of a screening 
period, 4-week blinded sequential ascending-dose phase, 
a 52-week open-label treatment-extension phase, and a 
52-week observational follow-up phase. A total number 
of 19 clinical sites were activated to recruit subjects (13 
sites in the United States and six sites in Canada), out of 
which 11 sites enrolled subjects (seven sites in the United 
States and four sites in Canada). The study population 
was restricted to subjects with an FVC >50 and <90 % of 
predicted, DLco >25 and <90 % of predicted, and resting 
saturated oxygen of >92  % on room air at sea level who 
have findings of usual interstitial pneumonia pattern on 
HRCT and/or usual interstitial pneumonia pattern on his-
topathology (i.e., lung biopsy), and the exclusion of known 
causes of interstitial lung disease. The primary endpoint 
of the study was to evaluate the safety (clinical adverse 
events (AE), laboratory, or other changes) of CC-930 in 
the 4-week double-blind treatment phase. Secondary 
endpoints included: CC-930 pharmacokinetics; evalu-
ation of the long-term safety of CC-930 in the 52-week 
open-label extension; and disease progression and death 
rates within the total treatment and follow-up observa-
tional period. Exploratory endpoints included: changes in 
blood biomarkers KL-6, MMP-1, MMP-7, SP-A and SP-D, 
TIMP-1, CCL-18, CCL-2, PAI-1, and tenascin C; changes 
in FVC and DLCO from baseline; and change in HRCT 
pulmonary fibrosis score from baseline. The double-blind, 
ascending-dose phase consisted of three sequential dose 
cohorts [CC-930 50  mg QD (cohort 1), CC-930 100  mg 
QD (cohort 2), and CC-930 100  mg BID (cohort 3)]. In 
each cohort, eligible patients were randomly allocated to 
receive placebo (two patients) or CC-930 (eight patients) 
for 4 weeks. The decision to escalate to the next dose level 
was made after all patients had completed or discontin-
ued prematurely from the preceding dose level, and phar-
macokinetic and safety data from the preceding dose level 
had been reviewed by an external data monitoring com-
mittee. Ongoing review of blinded safety data from eight 
patients receiving CC-930 100 mg BID (cohort 3) revealed 
increases in liver transaminases that may have been a 
potential risk to patients if they continued at that dose. 
This observation led to the issuing of a protocol amend-
ment to decrease the study drug dose in Cohort 3 from 
100 mg BID to 100 mg QD (3 of 8 subjects remained on 
study and were dose-reduced). The data from these 3 sub-
jects were handled on an intent-to-treat basis. All patients 
who completed the double-blind, ascending-dose phase 
were eligible to enter the open-label treatment-exten-
sion phase and continue on the same dose of CC-930 
for 52  weeks. Patients initially allocated to placebo were 
given the CC-930 dose from their original cohort assign-
ment. The external data monitoring committee regularly 
reviewed safety results during this phase.
Subjects
In the phase I clinical study, healthy male and female vol-
unteers from any race were eligible to participate if they 
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were aged 18–50 years and had Fitzpatrick skin type I or 
II. Subjects were excluded if they had any serious medical 
condition or history of major medical condition within 
3 years of study, any prescribed systemic or topical medi-
cation within 30 days of first dose administration, or any 
surgical or medical conditions that could affect drug 
pharmacokinetics.
In the phase II IPF clinical study, patients were eli-
gible to participate if they had confirmed IPF based on 
American Thoracic Society/European Respiratory Soci-
ety guidelines, with an FVC of 50–90 % of predicted and 
a DLCO of 25–90 % of predicted. Patients were excluded 
for resting oxygen saturation <92  % on room air at sea 
level or <88 % at ≥5000 feet2 above sea level; pulmonary 
arterial hypertension, emphysema, or other significant 
respiratory disorders; current smoker; connective tissue 
disorder; significant medical conditions or laboratory 
abnormalities or history of clinically significant medi-
cal conditions that would prevent study participation or 
put patients at risk; history of serious cardiac conditions 
within 6 months of study entry; and ECG abnormalities.
Assessments
In the phase I clinical study, a small area of skin on the 
buttocks was exposed to 2 times the minimal erythema 
dose of UVB at 2 h after dosing on day 6. This exposure 
to UVB has previously been demonstrated to activate 
JNK and subsequently increase phosphorylation of its 
substrate c-Jun [31]. A skin punch biopsy was taken from 
the irradiated area 8 h after UVB. The skin specimen was 
analyzed for phospho-c-Jun. IHC images were quanti-
fied using a semi-quantitative scale from 0 to 4, in which 
higher scores indicated more intense immunostaining. 
Pharmacokinetic analyses were conducted using blood 
samples collected on day 1 predose and at 1, 2, 3, 6, 10, 
and 24  h post-dose. Safety assessments included moni-
toring of AEs, vital signs, 12-lead ECGs, and clinical lab-
oratory tests.
In the phase II IPF clinical study, patients were 
screened within 5 weeks before the double-blind, ascend-
ing-dose phase. Study visits were scheduled at weeks 
0 (baseline), 1, 2, and 4 of the double-blind, ascending-
dose phase, and at weeks 5, 6, and 8, and every 4 weeks 
thereafter until the final treatment visit at week 56 or at 
the early termination visit. Subsequent observational fol-
low-up visits were planned quarterly. Safety assessments, 
including AEs, vital signs, 12-lead ECGs, and clinical lab-
oratory tests, were performed at each visit. A complete 
physical examination was done at screening and at the 
end of each treatment phase; a targeted physical exami-
nation was done at all other visits. Holter monitoring 
was done within 10 days of the first dose of study treat-
ment and at weeks 1, 5, and 16. Chest radiographs were 
obtained at screening and at the final treatment/early ter-
mination visit.
To monitor the disease course, spirometry and DLCO 
assessments were made at baseline, every 4  weeks until 
week 24, and every 8 weeks thereafter. The HRCT/fibrosis 
score was determined at screening and at the final treat-
ment/early termination visit. Disease progression was 
defined as death from respiratory failure, progressive sus-
tained decrease in FVC or DLCO, unexplained worsening 
of hypoxia, or acute exacerbation. Other efficacy param-
eters, including changes from baseline in FVC, DLCO, and 
HRCT/fibrosis score, were exploratory endpoints.
Blood was collected at baseline and at weeks 4, 24, and 
56 for measurement of MMP-1, MMP-7, TIMP-1, tenas-
cin-C, SP-A, SP-D, CCL-18, KL-6, MCP-1, and PAI-1. 
All ten biomarkers were assayed using validated enzyme-
linked immunosorbent assays or other similar methods 
by Pacific Biomarkers, Inc (Seattle, WA). For the pharma-
cokinetics analysis, a subset of patients volunteered for 
intense blood sampling on day 1 and week 2; all others 
had sparse sampling at week 2. Sparse sampling was also 
done at weeks 8, 12, 16, 20, 24, 32, 40, 48, and 56. The 
plasma concentration of CC-930 and its major circulat-
ing and pharmacologically inactive metabolite CC-17172 
were measured using a validated liquid chromatography–
tandem mass spectrometry method.
Statistical analysis
Safety parameters were evaluated in all patients who 
received ≥1 dose of study drug using descriptive statis-
tics. Treatment-emergent AEs were coded to the Medical 
Dictionary for Regulatory Activities (version 14.0). Phar-
macokinetics and pharmacodynamics were evaluated in 
all patients from the safety population who had ≥1 phar-
macokinetic and ≥1 biomarker assessment, respectively. 
In the phase I study in healthy volunteers, phospho-c-Jun 
IHC images were scored by three independent evalua-
tors using a subjective scoring scale of 0–4 (increases in 
scores reflect higher immuno-staining). Individual phos-
pho-c-Jun scores were subtracted by the corresponding 
placebo to reflect the individual response to CC-930. A 
repeated measure logistic regression was performed on 
the IHC scores of total c-Jun and phospho-c-Jun using 
the GENMOD procedure in SAS version 9.2 (SAS Insti-
tute, Cary, NC). The model included sequence, period, 
and treatment as fixed effects. In the analysis, scores of 
0, 1, and 2 were grouped together (low score), and scores 
of 3 and 4 were grouped together (high score). All 14 sub-
jects in the pharmacodynamic population were included 
in the analysis. In the phase II IPF clinical study, changes 
from baseline in biomarker values were summarized sep-
arately for the double-blind, ascending-dose phase and 
the entire study using descriptive statistics.
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The CC-930 plasma concentration data from the phase 
II IPF clinical study were combined with data from a 
phase I study conducted in 13 healthy subjects to build 
a 2-compartment population pharmacokinetics model. 
Population modeling and simulation were performed 
using NONMEM® version 7.2 (Ellicott City, MD). Cor-
relations between the model-predicted individual expo-
sure to CC-930, as defined by the area under the plasma 
drug concentration-versus-time curve during the dosing 
interval, and the changes from baseline in MMP-7 were 
analyzed using a locally weighted polynomial regression 
method. Correlations between the changes from baseline 
in biomarker values versus changes from baseline in FVC 
percent of predicted were evaluated by Spearman’s corre-
lation coefficient (r) and the associated P value based on 
the asymptotic test for H0.
Results
HDM‑induced lung remodeling
The JNK inhibitor CC-930 had previously been tested in 
the mouse bleomycin-induced pulmonary fibrosis model, 
having shown a dose-dependent reduction in lung fibro-
sis scores [27]. However, in this model, MMP-7 levels 
were measured and found to not be induced by bleo-
mycin instillation. Therefore, we sought a different pre-
clinical model of lung fibrosis that might better reflect 
the biomarker changes seen in patients with IPF. For this 
reason, we explored the utility the HDM lung fibrosis 
model. To address the impact of CC-930 on the fibrotic 
airway remodeling associated with allergic airways dis-
ease, we exposed mice to the asthma-relevant allergen, 
HDM, over a time frame of 3 weeks, in the presence of 
CC-930 or vehicle control (Fig.  1a). Levels of phospho-
rylated c-Jun (phospho-c-Jun; reflective of JNK activa-
tion) in homogenized lung tissue were increased in mice 
exposed to HDM, as compared with PBS vehicle controls. 
As expected, the HDM-induced increase in phospho-c-
Jun was attenuated in mice pretreated with CC-930 com-
pared with vehicle controls (Fig. 1b).
HDM‑induced mucus metaplasia
We next addressed the impact of CC-930 on HDM-
induced mucus metaplasia, a prominent feature of aller-
gic airways disease. Comparable periodic acid-Schiff 
(PAS) reactivity was observed in CC-930-treated and 
vehicle-treated mice exposed to HDM (Fig.  2a). The 
airway mucin MUC5AC increased in CC-930-treated 
and vehicle-treated mice but reached statistical signifi-
cance only in mice exposed to HDM (Fig.  2b). MUC5B 
significantly increased in both HDM vehicle control 
groups, and again did not reach significance in the CC-
930-treated mice (Fig.  2c). Assessment of MUC5B by 
immunofluorescence showed strong increases in MUC5B 
reactivity in club cell secretory protein positive cells after 
HDM exposure, which was attenuated after administra-
tion of CC-930 (Fig. 2d). Overall, these findings demon-
strate that JNK did not appear to play a dominant role 
in mucus metaplasia despite the slight attenuations of 
MUC5B that were observed in CC-930-treated mice.
HDM‑induced airway remodeling
The effect of CC-930 on HDM-induced fibrotic air-
way remodeling was analyzed histopathologically using 
the Masson’s trichrome collagen stain. In response to 
HDM, collagen content was significantly enhanced 
around the bronchioles, consistent with earlier obser-
vations [29]. Remarkably, in mice receiving CC-930, 
the HDM-induced peribronchiolar deposition of col-
lagen was significantly attenuated, while vehicle-treated 
mice exposed to HDM showed increases in peribron-
chiolar collagen deposition similar to those observed in 
HDM-exposed mice (Fig.  3a). Quantitative assessment 
of soluble and total lung collagen content demonstrated 
decreases in CC-930-treated mice compared with vehicle 
controls exposed to HDM (Fig.  3b, c). HDM-mediated 
increases in collagen 1A1 mRNA also were reduced in 
CC-930-treated mice compared with HDM vehicle con-
trols (Fig.  3d). In comparison, α-smooth muscle actin 
(α-SMA), E-cadherin, and SP-D (see Additional file  1: 
Figure S1), as well as collagen 4 and collagen 5, were not 
significantly affected in mice exposed to HDM (Fig. 3e). 
TGF-β1 is a major pro-fibrogenic growth factor that 
has been implicated in lung fibrosis, and cooperation 
between JNK and TGF-β1 signaling has been observed 
[30]. HDM led to marked increases of TGF-β1 in bron-
choalveolar lavage, which was not affected by CC-930 or 
vehicle, suggesting that TGF-β1 is activated proximally to 
or independent of JNK (see Additional file 1: Figure S2a). 
Overall, these findings demonstrate that CC-930 had 
a protective effect on lung collagen deposition in mice 
exposed to HDM.
HDM‑induced airway inflammation and airway 
hyperresponsiveness
Major features of HDM-induced disease are airway 
inflammation and hyperresponsiveness to methacholine. 
HDM-induced airway inflammation and hyperrespon-
siveness were not significantly affected by CC-930 (Addi-
tional file 1: Figure S3). These findings are consistent with 
prior observations in JNK1-/- mice exposed to HDM, 
which showed patterns of airway inflammation and 
hyperresponsiveness comparable to wild-type mice [29].
HDM‑induced MMP‑7 protein and gene expression
MMP-7 has been identified as a biomarker for IPF [11]. 
An IHC evaluation of MMP-7 revealed robust increases 
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in reactivity in lung tissues from HDM-treated mice 
compared with PBS-treated mice, with notable reac-
tivity occurring in the bronchiolar epithelium (Fig. 4a). 
Similarly, after HDM exposure, increases in MMP-7 
were observed in BALF (Fig.  4b) and serum (Fig.  4c). 
mRNA expression of MMP-7 was also increased in 
homogenized lung tissue from mice exposed to HDM, 
as compared with PBS vehicle controls (Fig.  4d). 
Administration of CC-930, but not vehicle control, led 
to attenuation in HDM-mediated increases in MMP-
7. These findings suggest a role for JNK in regulat-
ing MMP-7 expression in settings of fibrotic airway 
remodeling.
Phase I pharmacokinetic, pharmacodynamic, and safety 
study of CC‑930 in healthy volunteers
Fifteen subjects were enrolled, and 14 (93.3  %) com-
pleted each of the three 6-day study periods (treatment 
with placebo, CC-930 75  mg QD, and CC-930 200  mg 
QD). The mean age of the study cohort was 31  years 
(range: 20–49 years); 100 % were white and 100 % were 
male. CC-930 administered for 6 days at doses of 75 mg 
QD and 200  mg QD was well tolerated in the healthy 
subjects. No subject discontinued because of an adverse 
event (AE), and no serious AEs were reported.
The mean CC-930 plasma concentration was 0.81 µM 
at the 75  mg QD dose and 1.89  µM at the 200  mg QD 
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Fig. 1 C‑Jun phosphorylation in HDM‑challenged mice and the impact of CC‑930 or vehicle control. a Schematic depicting the time course of 
HDM exposure and CC‑930 administration. For instillation, 50 µg HDM or PBS as the vehicle control was administered intranasally once for 5 days 
over 3 weeks at the days indicated via the top arrows. Vehicle control (0.5 % CMC/0.25 % Tween 80) or CC‑930 (100 mg/kg) was administered twice 
daily on the days indicated via the bottom arrows. Mice were euthanized 72 h after the last challenge. b Lung tissue was homogenized from PBS 
or HDM‑challenged mice for assessment of phospho‑c‑Jun. Equal amounts of protein (20 μg for phosho‑c‑jun, 5 μg for actin) were separated 
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and subjected to Western blot analysis for phospho‑c‑Jun and actin. 
Band intensity was determined and expressed as a ratio of phosphorylation to total protein (actin). Data shown represent mean ± SEM from two 
independent experiments (PBS: n = 10; HDM alone: n = 10; HDM + vehicle control: n = 11; HDM + CC‑930: n = 11). *P < 0.05 (analysis of variance) 
versus PBS. †P < 0.05 versus the HDM group
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dose. The ability of CC-930 to inhibit JNK was deter-
mined by measuring phospho-c-Jun by IHC in skin 
punch biopsy specimens at 8  h after UVB exposure 
(Additional file 1: Figure S4). CC-930 partially or nearly 
completely inhibited the phospho-c-Jun elevation in 8 
of 14 (57.1 %) subjects receiving 75 mg QD and in 11 of 
14 (78.6  %) subjects receiving 200  mg QD. The median 
IHC score for phospho-c-Jun on a semi-quantitative 0–4 
scale was 4 with placebo, 3 with CC-930 75 mg QD, and 
1 with CC-930 200 mg QD. The odds ratio of achieving 
a low IHC score (0, 1, or 2) was 11.0 with CC-930 75 mg 
QD (P  =  0.016) and 41.9 with CC-930 200  mg QD 
(P = 0.005).
Phase II efficacy, safety, and pharmacodynamic study 
of CC‑930 in patients with IPF
The study design is shown in Additional file  1: Fig-
ure S5. In total, 28 IPF patients were randomized to 
study treatment. Of these, 26 (92.9  %) patients com-
pleted the 4-week, placebo-controlled, double-blind, 
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ascending-dose phase and entered the 52-week open-
label treatment-extension phase (Additional file 1: Figure 
S6). The study cohort had a mean age of 67.1 years; most 
patients were white (92.9 %) and male (71.4 %) (Table 1). 
Patient demographics were generally well balanced 
across treatment groups; however, patients allocated to 
CC-930 100 mg QD were younger and more obese than 
those in the other groups. Baseline disease characteristics 
were generally well balanced across treatment groups. 
Diagnosis of IPF was conducted via high-resolution CT 
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Fig. 3 Impact of CC‑930 or vehicle on HDM‑induced fibrotic airway remodeling. a Histopathological analysis of Masson’s trichrome‑stained airway 
sections in mice exposed to PBS, HDM alone, HDM + vehicle, or HDM + CC‑930 (magnification: 200×). Assessment of total collagen content by  
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(HRCT) for a majority of subjects (60.7  %); however, a 
greater majority of 100 mg QD subjects were diagnosed 
with IPF via histopathology (75.0 %) compared with pla-
cebo (0.0 %), 50 mg QD (12.5 %), and 100 mg BID (0.0 %) 
subjects. The mean FVC was 67.1 % of predicted and the 
mean DLCO was 41.5 % of predicted. Six patients entered 
the study receiving supplemental oxygen. Prior medi-
cation use was generally similar across the treatment 
groups; however, the proportion of patients with prior 
respiratory system therapies was lower for the CC-930 
100  mg BID group (29  %) compared with the placebo, 
CC-930 50 mg QD, and CC-930 100 mg QD dose groups 
(60, 63 and 88 %, respectively).
Patients were exposed to CC-930 and placebo for 
a mean of 3.8 and 4.0  weeks, respectively, during the 
double-blind, ascending-dose phase. Total mean expo-
sure to CC-930 during the entire treatment period, 
including that of patients who switched from placebo 
on entry into the open-label treatment-extension phase, 
was 25.9  weeks. Mean exposure decreased in a dose-
dependent manner: 38.8 weeks with CC-930 50 mg QD, 
22.5 weeks with CC-930 100 mg QD, and 7.8 weeks with 
CC-930 100  mg BID. Three patients receiving CC-930 
100 mg BID were switched to CC-930 100 mg QD based 
on an ongoing blinded safety review and received the 
lower dose for a mean of 21.2 additional weeks.
Safety
The frequency of AEs during the double-blind, ascend-
ing-dose phase appeared to increase in a dose-related 
manner with CC-930 (12.5  % with 50  mg QD, 62.5  % 
with 100 mg QD, and 71.4 % with 100 mg BID) (Table 2). 
The only AEs experienced by ≥2 patients were dizzi-
ness (14.3  %), upper respiratory tract infection (7.1  %), 
headache (7.1  %), and nausea (7.1  %); in each case, the 
AEs occurred in patients receiving CC-930 at a dose of 
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Fig. 4 HDM‑induced MMP‑7 protein and gene expression is attenuated by CC‑930. a MMP‑7 immunohistochemistry staining of mouse lungs 
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measured by the enzyme‑linked immunosorbent assay and d mRNA expression of MMP‑7 in lung homogenates measured by q‑PCR mice after 
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100 mg QD or 100 mg BID. When the double-blind and 
open-label treatment-extension phases were combined, 
the most frequently reported AEs were increased alanine 
aminotransferase (ALT), increased aspartate aminotrans-
ferase (AST), and upper respiratory tract infection (each 
21.4  %), as well as bronchitis, nasopharyngitis, dizzi-
ness, and increased lactate dehydrogenase (each 14.3 %). 
The increases in ALT, AST, and lactose dehydrogenase 
mostly occurred in patients receiving a dose of 100  mg 
BID. No deaths were reported during the CC-930 treat-
ment period. Two patients died during the observational 
follow-up period; the causes of death were respiratory 
failure and secondary due to IPF. Both patients had 
received their last dose of CC-930 100  mg QD at least 
50  days before their death. Three patients had serious 
AEs, including 1 during the double-blind, ascending-
dose phase (Clostridium difficile colitis), and 2 during the 
open-label treatment-extension phase (pneumonia and 
increased ALT/AST).
Overall, 13 patients discontinued CC-930 because of 
AEs, with the frequency increasing in a dose-related 
manner (20 % with 50 mg QD, 50 % with 100 mg QD, and 
75  % with 100  mg BID). The only AEs resulting in dis-
continuation of >1 patient were increased lactate dehy-
drogenase (n = 4), increased ALT (n = 3), and increased 
AST (n = 3), all of which occurred in patients receiving 
CC-930 100 mg BID. The six patients who discontinued 
because of increased ALT or AST were the only patients 
with ALT or AST values >3 times the upper limit of nor-
mal. None of these cases was accompanied by concur-
rent alkaline phosphatase or bilirubin values >2 times 
the upper limit of normal, and none met the criteria for 
Hy’s law. All hepatic transaminase elevations resolved 
within 2–4 weeks after discontinuation of CC-930. Three 
patients discontinued because of cardiac-related AEs; it 
is not known if these were related to the age and health 
of the patients or occurred as a consequence of CC-930. 
Because the benefit/risk profile of CC-930 did not sup-
port continuation, this study was terminated early during 
the extension phase.
Pharmacokinetics
CC-930 was rapidly absorbed following oral adminis-
tration, with mean peak plasma drug concentrations 
achieved by approximately 1 h (Additional file 1: Figure 
S7). Pharmacokinetic parameters were determined for 
four patients randomized to CC-930 100  mg QD who 
participated in the intensive pharmacokinetic substudy. 
None of the patients allocated to CC-930 50 mg QD or 
CC-930 100 mg BID volunteered for this substudy. After 
the first dose, the mean peak plasma concentration of 
CC-930 was 674  ng/mL and the mean exposure until 
8 h post-dose (AUC0–8) was 3339 ng·h/mL. These values 
increased to 1040 ng/mL and 5912 ng·h/mL, respectively, 
when measured after daily dosing for 2 weeks. The accu-
mulation ratio for CC-930 was approximately 1.8-fold, 
consistent with a terminal half-life of 25–31 h, as previ-
ously measured in healthy volunteers (data not shown). 
Because samples were taken only until 8  h postdose in 
this IPF study, the PK parameters of terminal phase half-
life, apparent total clearance, and apparent volume of dis-
tribution cannot be accurately determined in this patient 
population and are therefore not reported.
Pharmacodynamics
CC-930 reduced median plasma MMP-7 concentra-
tions in a dose-related manner during the double-blind, 
ascending-dose phase; the same trend continued during 
Table 1 Baseline patient demographic and clinical characteristics in the idiopathic pulmonary fibrosis study
FVC forced vital capacity; DLCO diffusing capacity for carbon monoxide; SpO2 saturation of peripheral oxygen
Placebo
n = 5
CC‑930 All patients
N = 28
50 mg QD
n = 8
100 mg QD
n = 8
100 mg BID
n = 7
Age, mean (±SD), years 67.2 (±3.90) 70.0 (± 6.82) 62.0 (±7.98) 69.7 (±7.02) 67.1 (±7.33)
Males, n (%) 3 (60.0) 8 (100.0) 5 (62.5) 4 (57.1) 20 (71.4)
Race, n (%)
 Black 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 1 (3.6)
 Native  Hawaiian/Pacific Islanders 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 1 (3.6)
 White 5 (100.0) 7 (87.5) 7 (87.5) 7 (100.0) 26 (92.9)
 Weight, mean (±SD), kg 85.6 (±8.51) 96.8 (±16.58) 93.4 (±15.02) 76.0 (±16.49) 88.6 (±16.46)
 Body mass index, mean (±SD), kg/m2 28.8 (±2.70) 29.7 (±4.23) 31.1 (±2.62) 27.0 (±2.53) 29.3 (±3.37)
 FVC percent of predicted, mean (±SD) 62.3 (±12.10) 68.2 (±6.84) 66.2 (±11.56) 70.2 (±5.58) 67.1 (±9.10)
 DLCO percent of predicted, mean (±SD) 38.6 (±4.44) 39.3 (±7.05) 45.2 (±15.29) 41.9 (±7.28) 41.5 (±9.76)
 SpO2 mean (±SD), % 96.6 (±1.95) 95.1 (±1.81) 96.0 (±1.31) 94.7 (±1.70) 95.5 (±1.73)
 Supplemental oxygen use, n (%) 1 (20.0) 0 (0.0) 3 (37.5) 2 (28.6) 6 (21.4)
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the open-label treatment-extension phase (Fig.  5a). The 
changes in plasma MMP-7 concentrations from baseline 
to week 4 were correlated with the CC-930 dose (Fig. 6a) 
and with exposure predicted from the population phar-
macokinetic model (Fig.  6b). The percent changes from 
baseline in SP-D concentrations trended lower with 
increasing CC-930 dose (Fig.  5b). CC-930 at doses of 
50 mg QD and 100 mg QD lowered median tenascin-C 
levels during the double-blind, ascending-dose phase, but 
little change was observed in patients receiving CC-930 
Table 2 Overview of AEs in the idiopathic pulmonary fibrosis study
Double‑blind treatment period, patients, n (%) Placeboa
n = 5
CC‑930
50 mg QD
n = 8
100 mg QD
n = 8
100 mg BID
n = 7
Total
N = 28
≥1 AE 3 (60.0) 1 (12.5) 5 (62.5) 5 (71.4) 14 (50.0)
≥1 severe AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
≥1 serious AE 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 1 (3.6)
AE leading to drug withdrawal 0 (0.0) 0 (0.0) 1 (12.5)b 1 (14.3) 2 (7.1)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE in ≥2 patients (in any treatment group)
 Dizziness 0 (0.0) 0 (0.0) 2 (25.0) 2 (28.6) 4 (14.3)
 Upper respiratory tract infection 0 (0.0) 0 (0.0) 1 (12.5) 1 (14.3) 2 (7.1)
 Headache 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 2 (7.1)
 Nausea 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 2 (7.1)
CC‑930 exposure period, patients, n (%) CC‑930 Total
N = 28
50 mg QD
n = 10
100 mg QD
n = 10
100 mg BID
n = 8
≥1 AE 7 (70.0) 9 (90.0) 8 (100.0) 24 (85.7)
≥1 severe AE 0 (0.0) 2 (20.0) 1 (12.5) 3 (10.7)
≥1 serious AE 0 (0.0) 1 (10.0) 2 (25.0) 3 (10.7)
AE leading to drug withdrawal 2 (20.0) 5 (50.0) 6 (75.0) 13 (46.4)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE in ≥2 patients (in any treatment group)
 Increased alanine aminotransferase 0 (0.0) 1 (10.0) 5 (62.5) 6 (21.4)
 Increased aspartate aminotransferase 0 (0.0) 1 (10.0) 5 (62.5) 6 (21.4)
 Upper respiratory tract infection 2 (20.0) 2 (20.0) 2 (25.0) 6 (21.4)
 Increased blood lactate dehydrogenase 0 (0.0) 0 (0.0) 4 (50.0) 4 (14.3)
 Bronchitis 2 (20.0) 2 (20.0) 0 (0.0) 4 (14.3)
 Nasopharyngitis 1 (10.0) 2 (20.0) 1 (12.5) 4 (14.3)
 Dizziness 0 (0.0) 2 (20.0) 2 (25.0) 4 (14.3)
 Headache 1 (10.0) 2 (20.0) 0 (0.0) 3 (10.7)
 Sinusitis 1 (10.0) 1 (10.0) 1 (12.5) 3 (10.7)
 Diarrhea 0 (0.0) 3 (30.0) 0 (0.0) 3 (10.7)
 Nausea 0 (0.0) 2 (20.0) 0 (0.0) 2 (7.1)
 Viral gastroenteritis 0 (0.0) 1 (10.0) 1 (12.5) 2 (7.1)
 Increased C‑reactive protein 0 (0.0) 2 (20.0) 0 (0.0) 2 (7.1)
 Muscle spasms 0 (0.0) 1 (10.0) 1 (12.5) 2 (7.1)
 Musculoskeletal chest pain 0 (0.0) 2 (20.0) 0 (0.0) 2 (7.1)
 Rash 1 (10.0) 0 (0.0) 1 (12.5) 2 (7.1)
 Cough 1 (10.0) 1 (10.0) 0 (0.0) 2 (7.1)
 Productive cough 1 (10.0) 0 (0.0) 1 (12.5) 2 (7.1)
AE adverse event; ALT alanine aminotransferase; AST increased aspartate aminotransferase
a Includes placebo patients from groups receiving CC-930 50 mg QD, 100 mg QD, and 100 mg BID
b Patient discontinued after completing the double-blind treatment phase but before enrolling in the open-label treatment phase
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100 mg BID. During the open-label treatment-extension 
phase, tenascin-C concentrations returned toward base-
line over time and then surpassed baseline levels by the 
final assessment (Fig.  5c). No trends were observed for 
the other 7 biomarkers assayed (data not shown).
Efficacy
Forced vital capacity remained largely unchanged in 
this study through week 32 (Fig. 7). Notably, there was a 
pronounced decline in FVC after drug withdrawal. Dis-
ease progression was reported for nine (32.1 %) patients. 
Three (30.0 %) patients who received CC-930 50 mg QD 
and five (50.0 %) patients who received CC-930 100 mg 
QD showed disease progression during the 4-week 
observational follow-up period. One (12.5 %) patient who 
received CC-930 100  mg BID showed disease progres-
sion on day 50 during the open-label treatment-extension 
phase. When all visits were considered for all patients, 
the changes in FVC percent of predicted were corre-
lated with changes in plasma concentrations of MMP-7 
(r = −0.397; P = 0.008), SP-D (r = −0.310; P = 0.04), and 
tenascin-C (r = −0.523; P < 0.001) (Fig. 8).
The HRCT/fibrosis score at the patients’ last on-treat-
ment visit was compared with their baseline score. The 
median duration between the baseline and last HRCT/
fibrosis score was 58.3  weeks for patients receiving 
CC-930 50  mg QD, 25.0  weeks for patients receiving 
CC-930 100 mg QD, and 16.3 weeks for patients receiv-
ing CC-930 100  mg BID. The HRCT/fibrosis score sug-
gested disease stabilization instead of progression in 1 of 
9 (11.1 %) patients receiving CC-930 50 mg QD, 6 of 10 
(60.0 %) receiving CC-930 100 mg QD, and 3 of 7 (42.9 %) 
receiving CC-930 100  mg BID. HRCT data were miss-
ing for the other 2 patients. Improvements in reticular 
abnormality and honeycombing were not observed.
During the double-blind treatment phase, the classes of 
concomitant medications used in at least 50 % of overall 
subjects were cardiovascular system (75.0 %), alimentary 
tract and metabolism (71.4  %), and respiratory system 
(57.1 %). The frequency of subjects with concomitant use 
of respiratory system therapies was lower for the 100 mg 
BID group (42.9  %) compared with the placebo, 50  mg 
QD, and 100 mg QD dose groups (60.0, 50.0 and 75.0 %, 
respectively). During the open-label treatment phase, 
the classes of concomitant medications used in at least 
50 % of subjects were cardiovascular system (84.6 %), ali-
mentary tract and metabolism (73.1 %), respiratory sys-
tem (73.1 %), nervous system (61.5 %), anti-infectives for 
systemic use (57.7  %), blood and blood-forming organs 
(53.8 %), and musculoskeletal system (53.8 %). As in the 
double-blind treatment phase, the frequency of subjects 
with concomitant use of respiratory system therapies was 
lower for cohort 3 (42.9 %) compared with the cohorts 1 
and 2 (88.9 and 80.0 %, respectively).
Discussion
JNK1 recently has been shown to play an important role 
in the pathogenesis of bleomycin and TGF-β1-induced 
lung fibrosis [26] and in HDM-induced fibrotic air-
way remodeling, while not affecting inflammatory cell 
recruitment, airway hyperresponsiveness, or mucus 
metaplasia [29]. In the present study, we demonstrated 
that CC-930, the pharmacological inhibitor of JNK, 
inhibited HDM-mediated increases in phospho-c-Jun 
in lung tissue. CC-930 did not affect HDM-induced 
inflammation, airway hyperresponsiveness, or mucus 
metaplasia, consistent with earlier observations using 
JNK1-/- mice [29]. However, our data show that CC-930 
significantly reduced MMP-7 protein and mRNA expres-
sion, and attenuated peribronchiolar fibrotic remodeling 
and collagen deposition. These preclinical results support 
the potential of CC-930 as a viable candidate for treating 
fibrotic airways disease.
Results from the healthy volunteer phase I study dem-
onstrate that CC-930 inhibits JNK in human subjects in 
a dose-related manner. JNK inhibition was determined 
by IHC of phospho-c-Jun in UVB-exposed skin, a model 
that depends on JNK activation and subsequent phos-
phorylation of its substrate c-Jun [31]. At the time of skin 
biopsy, mean CC-930 plasma concentration was 0.81 µM 
with the 75 mg QD dose and 1.89 µM with the 200 QD 
dose. These concentrations were comparable to IC50 val-
ues determined in cell-based studies. CC-930 inhibited 
UVB-induced phospho-c-Jun in cultured normal human 
epidermal keratinocytes with IC50 values between 0.1 
and 3.0 μM, and it reduced growth factor-induced c-Jun 
phosphorylation and basal collagen protein expression in 
human fibroblasts from scleroderma patients at a con-
centration of 1 μM [28]. Results from this proof-of-con-
cept study were therefore consistent with the cell culture 
studies and provided the basis for the doses selected in 
the phase II study.
The IPF phase II study enrolled a well-defined popu-
lation of IPF patients with mild to moderate pulmo-
nary function impairment. The primary objective was 
to evaluate the pharmacokinetics, pharmacodynamics, 
biologic activity, and safety of CC-930. Pharmacokinetic 
data indicated that CC-930 is rapidly absorbed following 
oral administration, with pharmacokinetic parameters 
similar to those observed previously in phase 1 partici-
pants. The change in FVC was an exploratory endpoint, 
and was included in the definition of disease progression 
used herein. Deterioration in FVC ≥10 % from baseline 
over 6  months has been shown to predict mortality in 
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Fig. 5 Median change from baseline in a plasma MMP‑7, b surfactant protein D, and c tenascin‑C in all treatment groups throughout the 56‑week 
study
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IPF patients [32]. The mean FVC percent of predicted 
remained relatively stable at least through week 32. 
Moreover, only 9 (32.1  %) patients experienced disease 
progression; for eight of these patients, it was identified 
during the observational follow-up period. These find-
ings suggest that CC-930 may stabilize disease as long 
as patients remain on treatment. However, no definitive 
conclusion can be drawn on whether these data reflect 
the natural history of disease or are an actual benefit of 
CC-930 treatment. The apparently greater benefit of the 
higher doses of CC-930 may have reflected an imbalance 
in risk of progression despite the randomization scheme. 
Patients receiving CC-930 100 mg BID had a higher base-
line FVC percent of predicted than the other patients and 
also had a lower history of smoking and required fewer 
respiratory medications at baseline.
In the pharmacodynamic assessment, CC-930 reduced 
plasma MMP-7 and SP-D concentrations in a dose-
dependent manner. Notably, the reduction in MMP-7 
correlated with the population pharmacokinetic model-
predicted exposure to CC-930, and the changes in plasma 
MMP-7 and SP-D significantly correlated with changes 
in pulmonary function (FVC percent of predicted) when 
data for all patients and from all visits were considered. 
As noted, elevated MMP-7 levels have been identified 
in IPF patients and are negatively correlated with FVC 
and DLCO [11]. Moreover, higher plasma MMP-7 lev-
els have been associated with mortality in IPF patients 
[8]. CC-930 also reduced plasma tenascin-C concentra-
tions, at least at the two lower doses, and the changes 
in plasma tenascin-C were significantly correlated with 
FVC percent of predicted. However, at the highest dose, 
tenascin-C levels were only marginally reduced from 
baseline. Tenascin-C, an extracellular matrix glycopro-
tein expressed during wound healing, is a marker of both 
pulmonary fibrosis and hepatitis [33]. At the lower doses, 
the reduction in tenascin-C levels may have been driven 
by a beneficial drug effect in the lungs. At the highest 
dose, however, the drug’s effect on the liver may have 
increased plasma tenascin-C levels and countered any 
reduction achieved from a favorable lung effect.
The JNK pathway plays an important role in the regu-
lation of gene expression of MMP-7, SP-D, and tenascin-
C. For example, mesothelin enhances the invasiveness 
of ovarian cancer cells by inducing MMP-7 through 
activation of mitogen-activated protein kinase/extracel-
lular signal-regulated kinase and JNK pathways [34]; the 
human T cell leukemia virus type 1 Tax protein trans-
activates the MMP-7 gene via JunD/AP-1 signaling that 
is dependent on activation of JNK1/2 and extracellular 
signal-regulated kinase 1/2 [35]; and (-)-epigallocate-
chin-3-gallate stimulates pro-MMP-7 production via 
activation of the JNK1/2 pathway in HT-29 human colo-
rectal cancer cells [36]. Regulation of SP-D gene activ-
ity depends on interactions among relatively ubiquitous 
transcription factors, with the conserved AP-1 site 
required for maximal promoter activity [37]. Tenascin-
C gene expression in rat mesangial cells was down-
regulated by CC-930 10  μM (data on file, Celgene 
Corporation). Therefore, the observed downward trends 
in MMP-7, SP-D, and tenascin-C expression by CC-930 
treatment in the phase II clinical study are all biologically 
plausible. The observed correlations between the change 
in each of these proteins and the change in FVC percent 
of predicted suggest that JNK inhibition produces posi-
tive trends in pharmacodynamic markers that may be 
indicative of positive trends in pulmonary function in 
IPF patients. Whether these findings are reproducible, 
and whether a true positive effect in pulmonary function 
can be realized in an IPF population, will require further 
clinical studies with larger sample sizes and sufficient 
study duration.
Fig. 6 Median change from baseline in a plasma MMP‑7 concentra‑
tion at week 4 versus CC‑930 dose and b MMP‑7 versus CC‑930 expo‑
sure (AUC0−τ) predicted from the population pharmacokinetic model. 
a The dose was reduced from 100 mg BID to 100 mg QD within the 
first 4 weeks for one patient due to a protocol amendment
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Fig. 7 Mean change from baseline in FVC over time in idiopathic pulmonary fibrosis patients treated with CC‑930. a FVC percent predicted and  
b FVC in milliliters. a Defined as the last measurement on or before the day of the first dose of study drug. b 4 weeks post‑treatment visit. The 
follow‑up visit appears as a separate study week in the figure, with a dotted line connecting the last visit where subjects’ received drug to the follow‑
up visit. c Relative to the day of the first dose of study drug
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The initial 4-week, double-blind, ascending-dose 
phase did not reveal any meaningful difference in safety 
and tolerability between CC-930 and placebo. Although 
the frequency of AEs was higher in patients receiv-
ing CC-930 100 mg QD or 100 mg BID than in patients 
receiving CC-930 50  mg QD, it was still largely similar 
to the patients receiving placebo. All but two patients 
completed the double-blind, ascending-dose phase and 
entered the open-label treatment extension. Elevated 
hepatic transaminases were observed in patients receiv-
ing the highest doses of CC-930, mostly occurring after 
8–12  weeks of treatment. No proximate cause or risk 
factor was identified in any of these patients except for 
CC-930 treatment. Although these safety data indicate 
a dose-dependent, late-onset transaminitis that may 
be associated with liver injury, none of the cases met 
the criteria for Hy’s law, and each case resolved within 
2–4  weeks of discontinuing CC-930. Because of these 
observations, the study protocol was amended to reduce 
the dose of CC-930 from 100 mg BID to 100 mg QD for 
the three patients who remained in the study on treat-
ment. The effect of CC-930 was subsequently investi-
gated in human and rat primary hepatocytes in  vitro. 
No cytotoxicity was observed at clinically relevant con-
centrations of CC-930, and no specific toxicity related 
to the etiology of the transaminase elevations was iden-
tified (data not shown). In the literature, there are con-
flicting reports regarding the role of JNK in protection 
from liver damage. JNK1 knockout mice are resistant to 
high fat-diet induced excessive weight gain, insulin resist-
ance, and steatohepatitis. While JNK2 knockout mice 
develop obesity and insulin resistance similarly to normal 
mice, they exhibit increased ALT enzyme levels and liver 
cell apoptosis compared to normal mice high fat diet-
induced [38]. In mice fed a choline-deficient L-amino 
acid-defined (CDAA) diet, JNK1 knockout mice had less 
hepatic inflammation and fibrosis than normal mice, 
while JNK2 knockout mice on a CDAA diet exhibited 
hepatic inflammation, steatosis, and fibrosis comparable 
to levels observed in normal mice [39]. Thus there may be 
differential roles for JNK1 and JNK2 in protection from 
liver injury, however these findings are not consistent 
across different models, and reduction of JNK2 expres-
sion does not consistently have deleterious effects.
Several study limitations deserve mention. The study 
was blinded and placebo-controlled only for the first 
4  weeks, and study cohorts showed some imbalances 
despite the randomization. Both of these factors may 
have contributed to an overestimation of the effect of 
CC-930 on disease progression and exploratory efficacy 
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parameters. In addition, the study had a small sample size 
per dose level, which may have limited assessment of the 
potential benefit/risk profile of CC-930. Also, the study 
was stopped early, due to elevated hepatic transaminase 
levels, as described above.
Several other agents have been evaluated in similar 
IPF populations, and two agents, pirfenidone and nint-
edanib, have recently been approved for use in the United 
States [40, 41]. The limited clinical efficacy of these drugs 
necessitates the development of additional compounds 
in order to effectively combat disease. The present study 
highlights the potential clinical utility of targeting JNK in 
settings of fibrotic lung remodeling via CC-930.
Conclusion
In aggregate, we demonstrated that CC-930 attenuated 
phospho-c-Jun, MMP-7, and collagen deposition in a 
murine model of fibrotic airways remodeling. CC-930 
attenuated phospho-c-Jun in human subjects, and was 
well tolerated during the initial 4-week, double-blind, 
ascending-dose phase, but elevated liver enzymes were 
observed in some patients without identifiable risk factors 
who were treated with higher doses for 8–12  weeks. In 
IPF patients treated with CC-930, a decline in FVC per-
cent of predicted was observed after ≥6 months, although 
in the absence of a placebo control group beyond week 4 
in this treatment period, no conclusions about the effect 
of CC-930 on pulmonary function can be made. Changes 
in FVC were significantly correlated with changes in 
plasma MMP-7, SP-D, and tenascin-C concentrations. 
Furthermore, the changes in plasma MMP-7 were associ-
ated with CC-930 dose and exposure. These findings dem-
onstrate that it may be possible to use serum biomarkers 
to track disease progression in IPF patients as well as the 
potential clinical benefit of novel interventions.
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